CD274 and lung carcinoma: Though combining EGFR TKI plus PD(L)1 inhibitors does not warrant further development in EGFR-mutated lung cancer due to increased AEs outweighing the clinical activity observed, EGFR-directed therapy with EGFR antibodies such as cetuximab does not seem to exhibit the same toxicity and has been found to have signals of clinical activity when combined with PD(L)1 blockade.43